Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.
Roche Has Over Five Weight-Loss Companion Medicines, CEO Says
Roche has more than five medicines that it could combine with weight-loss drugs, Chief Executive Officer Thomas Schinecker said, as the Swiss drugmaker tries to crack the pharmaceutical industry's fastest-growing market. Speaking to Bloomberg Television, Schinecker said combination therapy could help treat kidney, liver and heart disease.
Roche targets more than $3 billion in annual obesity sales
Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics have the combined potential of more than 3 billion Swiss francs ($3.6 billion) in annual sales.
Roche's Lupus Study for Gazyva Meets Primary & Key Secondary Goals
RHHBY announces meeting primary and key secondary goals in the late-stage study of its lymphoma drug, Gazyva/Gazyvaro, for treating active lupus nephritis.
Roche: The Devil Is In The Details - Obesity Data Presentation Disappoints
Shares of Roche Holding AG pulled back this month after disappointing tolerability data was presented for CT-388 and CT-996 at the EASD conference. Roche sought the ceiling of safety and tolerability by aggressively increasing the doses of both candidates in these phase 1 trials. Future trials will have “start low and go slow” titration schemes which should improve tolerability of CT-388 and CT-996.
TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval
Shares of TG Therapeutics made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS and despite Roche receiving FDA approval for Ocrevus Zunovo. Ocrevus Zunovo's convenience profile does not look threatening and Roche believes it represents an incremental growth opportunity, primarily in treatment centers where IV infusions are not possible. Convenience should also be the third consideration for patients, after efficacy and safety, and Briumvi's position on both still looks strong.
Roche Antiviral Drug Reduces Transmission in Late-stage Study
Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected person to household members.
"Everyone Should Applaud" Powell for 50bps: Cullen Roche
Cullen Roche says the Fed is "thinking in a proactive sense" after announcing a 50BPS rate cut. He points to Fed Chair Jerome Powell's transparency to help "reduce the risk of a hard landing.
Healthy Returns: How competitive can Roche be in the weight loss drug market?
Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health market with acquisition of Veri.
RHHBY or ABBV: Which Is the Better Value Stock Right Now?
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Roche Holding AG (RHHBY) and AbbVie (ABBV). But which of these two stocks is more attractive to value investors?
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.
Roche Stock to Benefit From Accu-Chek Smartguide Launch in Europe
RHHBY's Accu-Chek Smartguide will provide several predictive features aimed at enhancing patient safety. However, the device may face tough competition from existing CGM devices.
